Sign inCreate account

Report workspace tools

NCT01010893COMPLETEDanonymous

Tolerability and Immunogenicity Study of FLUVAL P Monovalent Influenza Vaccine in Adults and Elderly Persons

Sponsor

Source record

Fluart Innovative Vaccine Ltd, Hungary

Phase

Source record

NA

Modality

AI-normalized

vaccine

Target

AI-normalized

Influenza

Indication / condition

AI-normalized

Influenza

Intervention

Source record

Vaccination with Fluval P and Fluval AB influenza vaccines, Vaccination with Fluval P monovalent influenza vaccine

Source & freshness

Source record

NCT ID

NCT01010893

Original source

ClinicalTrials.gov

Source last updated

May 21, 2012

Ingested at

May 30, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT01010893

Title

Tolerability and Immunogenicity Study of FLUVAL P Monovalent Influenza Vaccine in Adults and Elderly Persons

Sponsor

Fluart Innovative Vaccine Ltd, Hungary

Status

COMPLETED

Phase

NA

Condition raw

Influenza

Condition normalized

Influenza

Modality raw

Influenza

Modality normalized

vaccine

Target raw

Influenza

Target normalized

Influenza

Interventions

Vaccination with Fluval P and Fluval AB influenza vaccines, Vaccination with Fluval P monovalent influenza vaccine

Public preview

Source record

The clinical trial assessed the tolerability and immunogenicity of the FLUVAL P monovalent influenza vaccine in adults and elderly individuals. Conducted by Fluart Innovative Vaccine Ltd, the study aimed to verify the vaccine's efficacy and safety profile, particularly in the context of pandemic influenza prevention.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Tolerability and Immunogenicity Study of FLUVAL P Monovalent Influenza Vaccine in Adults and Elderly Persons

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT01010893

Status

COMPLETED

Phase

NA

Sponsor

Fluart Innovative Vaccine Ltd, Hungary

Executive brief

Investment-Ready Snapshot

The clinical trial assessed the tolerability and immunogenicity of the FLUVAL P monovalent influenza vaccine in adults and elderly individuals. Conducted by Fluart Innovative Vaccine Ltd, the study aimed to verify the vaccine's efficacy and safety profile, particularly in the context of pandemic influenza prevention.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedMay 21, 2012
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT01010893

Indication

Influenza

Modality

vaccine

Target

Influenza

Intervention

Vaccination with Fluval P and Fluval AB influenza vaccines, Vaccination with Fluval P monovalent influenza vaccine

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.